Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults with PKP2 Mutation-associated ARVC

计划入组 15 人 · 首次发布于 2024 年 1 月 29 日

Gene Therapy for ACM Due to a PKP2 Pathogenic Variant

计划入组 10 人 · 首次发布于 2023 年 10 月 31 日

Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

计划入组 200 人 · 首次发布于 2024 年 3 月 15 日

PKP2-gene therapy (LEXEO Therapeutics)

PKP2 AAV gene therapy (Renovacor)

PKP2-gene therapy (Tenaya Therapeutics)

Associated Capital

United States

Associated Medical Supplies Ltd

Canada

Associated Clinicians of East Texas, PLLC

United States

FDA Grants RMAT Designation to Tenaya's TN-401 Gene Therapy for PKP2-Associated ARVC

Tenaya Therapeutics Secures $8M CIRM Grant to Advance Gene Therapy Trial for Rare Heart Condition

Tenaya Therapeutics Reports Promising Early Results for TN-401 Gene Therapy in Rare Heart Disease